Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 413

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis

Open access
Zhang, Ting, Yin, Chaoran, Fedorov, Aleksandr, Qiao, Liangjun, Bao, Hongliang, Beknazarov, Nazar, Wang, Shiyu, Gautam, Avishekh, Williams, Riley M., Crawford, Jeremy Chase, Peri, Suraj, Studitsky, Vasily, Beg, Amer A., Thomas, Paul G., Walkley, Carl, Xu, Yan, Poptsova, Maria, Herbert, Alan, Balachandran, Siddharth·2022·Nature

Abstract

Only a small proportion of patients with cancer show lasting responses to immune checkpoint blockade (ICB)-based monotherapies. The RNA-editing enzyme ADAR1 is an emerging determinant of resistance to ICB therapy and prevents ICB responsiveness by repressing immunogenic double-stranded RNAs (dsRNAs), such as those arising from the dysregulated expression of endogenous retroviral elements (EREs)1–4. These dsRNAs trigger an interferon-dependent antitumour response by activating A-form dsRNA (A-RNA)-sensing proteins such as MDA-5 and PKR5. Here we show that ADAR1 also prevents the accrual of endogenous Z-form dsRNA elements (Z-RNAs), which were enriched in the 3′ untranslated regions of interferon-stimulated mRNAs. Depletion or mutation of ADAR1 resulted in Z-RNA accumulation and activation of the Z-RNA sensor ZBP1, which culminated in RIPK3-mediated necroptosis. As no clinically viable ADAR1 inhibitors currently exist, we searched for a compound that can override the requirement for ADAR1 inhibition and directly activate ZBP1. We identified a small molecule, the curaxin CBL0137, which potently activates ZBP1 by triggering Z-DNA formation in cells. CBL0137 induced ZBP1-dependent necroptosis in cancer-associated fibroblasts and reversed ICB unresponsiveness in mouse models of melanoma. Collectively, these results demonstrate that ADAR1 represses endogenous Z-RNAs and identifies ZBP1-mediated necroptosis as a new determinant of tumour immunogenicity masked by ADAR1. Therapeutic activation of ZBP1-induced necroptosis provides a readily translatable avenue for rekindling the immune responsiveness of ICB-resistant human cancers. A small molecule can bypass the RNA-editing enzyme ADAR1 to directly activate the Z-form nucleic acid sensor ZBP1, induce necroptosis in tumour fibroblasts and reverse resistance to immune checkpoint blockade in mouse models of melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04753-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 413

Metadata

Authors
Zhang, T., Yin, C., Fedorov, A., Qiao, L., Bao, H., Beknazarov, N., Wang, S., Gautam, A., Williams, R. M., Crawford, J. C., Peri, S., Studitsky, V., Beg, A. A., Thomas, P. G., Walkley, C., Xu, Y., Poptsova, M., Herbert, A., & Balachandran, S.
Venue
Nature
Published
2022-05-25
Volume
606
Issue
7914
Pages
594-602
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4281486773
Cited by
413
References
60
FWCI
22.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. https://app.cochat.ai/papers/10.1038/s41586-022-04753-7
The paper
Zhang, T., Yin, C., Fedorov, A., Qiao, L., Bao, H., Beknazarov, N., Wang, S., Gautam, A., Williams, R. M., Crawford, J. C., Peri, S., Studitsky, V., Beg, A. A., Thomas, P. G., Walkley, C., Xu, Y., Poptsova, M., Herbert, A., & Balachandran, S. (2022). ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. https://doi.org/10.1038/s41586-022-04753-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.